Cargando…
Discovery research and development history of the dopamine D(2) receptor partial agonists, aripiprazole and brexpiprazole
Otsuka Pharmaceutical Co., Ltd. successfully developed the first dopamine D(2) receptor partial agonist approved for schizophrenia, the antipsychotic aripiprazole (Abilify(®)). The drug was approved for this indication in the United States in 2002 and has received approval in the United States, Euro...
Autores principales: | Kikuchi, Tetsuro, Maeda, Kenji, Suzuki, Mikio, Hirose, Tsuyoshi, Futamura, Takashi, McQuade, Robert D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8340839/ https://www.ncbi.nlm.nih.gov/pubmed/33960741 http://dx.doi.org/10.1002/npr2.12180 |
Ejemplares similares
-
Synergistic anti‐depressive effect of combination treatment of Brexpiprazole and selective serotonin reuptake inhibitors on forced swimming test in mice
por: Amada, Naoki, et al.
Publicado: (2023) -
Brexpiprazole has a low risk of dopamine D(2) receptor sensitization and inhibits rebound phenomena related to D(2) and serotonin 5‐HT(2A) receptors in rats
por: Amada, Naoki, et al.
Publicado: (2019) -
The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder: an analysis of short-term and long-term studies
por: Weiss, Catherine, et al.
Publicado: (2018) -
Dopamine supersensitivity psychosis and dopamine partial agonist: A retrospective survey of failure of switching to aripiprazole in schizophrenia
por: Takase, Masayuki, et al.
Publicado: (2015) -
Effects of Dopamine D(2) Receptor Partial Agonist Antipsychotic Aripiprazole on Dopamine Synthesis in Human Brain Measured by PET with L-[β-(11)C]DOPA
por: Ito, Hiroshi, et al.
Publicado: (2012)